
Opinion|Videos|January 2, 2025
Impact of OSA on Patient Health and Comorbidities
Author(s)Aneesa Das, MD , Jeanne Caligiuri, MD
Panelists discuss how untreated obstructive sleep apnea (OSA) significantly increases patients’ risk of serious health complications, including cardiovascular disease, type 2 diabetes, depression, and cognitive impairment while exacerbating existing comorbidities.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.

The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.

Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Advertisement
Advertisement
Trending on Patient Care Online
1
Comparing VMS Therapy Effects on Menopausal Sleep
2
Ascletis Submits FDA IND for ASC30_39 Oral Obesity Combination
3
Individualizing Treatment for Menopausal Sleep Disturbances
4
American Cancer Society Updates Prostate Cancer Screening Guidelines
5
